Education
| School — Major — Degree | Duration |
|---|---|
|
國立國防醫學院 — 生命科學研究所(畢) — 博士 Doctorate, Life science, National Defense Medical Center, |
1995/08 — 1999/06 |
|
國立國防醫學院 — 微生物及免疫學研究所(畢) — 碩士 Master, Microbiology and immunology, National Defense Medical Center |
1991/08 — 1993/07 |
|
高雄醫學院 — 醫學技術學系(畢) — 學士 Bachelor, Medical Technology, Kaohsiung Medical College |
1987/09 — 1991/06 |
Intramural Experience
| Office/Department/Institute | Position | Duration |
|---|---|---|
| 臨床醫學研究部 Department of Medical Research | Director | — |
| 生物醫學暨環境生物學系 Department of Biomedical Science and Environmental Biology | Chair Professor | 2021/08/01 — 2024/07/31 |
| 生物醫學暨環境生物學系 Department of Biomedical Science and Environmental Biology | Professor | 2008/08/01 — |
| 生物醫學暨環境生物學系 Department of Biomedical Science and Environmental Biology | Associate Professor | 2005/08/01 — 2008/07/31 |
| 生物醫學暨環境生物學系 Department of Biomedical Science and Environmental Biology | Assistant Professor | 2003/08/01 — 2005/07/31 |
| 生物學系 Department of Biology | Assistant Professor | 2001/08/01 — 2003/07/31 |
Extramural Experience
Discipline
| NO | Discipline | Expertise |
|---|---|---|
| 1 | 生物醫農類 Biology, Medicine and Agriculture | 生物學之生化及分子生物 Biochemistry and Molecular Biology |
Research & Technology Platform Open to the Outside
Interested Area(s)for Interdisciplinary Research
1. 抗體藥物開發 2.奈米藥物傳輸 3. AI智慧藥物開發 4. 分子標記之分子造影平台 5. 藥物之細胞或動物療效評估 6. 定量或定性任何聚乙二醇修飾之分子(proteins、nanoparticle、liposome、free PEG...)之抗體或三明治技術平台 7. 抗體基因選殖與表現之技術平台(蛋白質藥物) 8. Microbiota研究
Area(s) of Expertise & Research
功能性分子造影、抗體基因工程、標靶奈米學、腫瘤免疫學、蛋白質體學AI抗體基因工程(人類化抗體)、抗體藥物、前驅抗體、雙功能抗體、標靶奈米藥物、非侵犯性分子造影、生物標記.
Antibody engineering, Gene therapy, Noninvasive imaging
Publication
| NO | Publication |
|---|---|
| 1 | Selective activation of IFNγ-ipilimumab enhances the therapeutic effect and safety of ipilimumab. Selective activation of IFNγ-ipilimumab enhances the therapeutic effect and safety of ipilimumab. |
| 2 | Exploring the therapeutic potential of DV-B-120 as an inhibitor of dengue virus infection. Exploring the therapeutic potential of DV-B-120 as an inhibitor of dengue virus infection. |
| 3 | 富馬酸水合酶通過失活 AMPK 和上調 DAB2 抑制非小細胞肺癌轉移 Fumarate hydratase inhibits non‑small cell lung cancer metastasis via inactivation of AMPK and upregulation of DAB2 |
| 4 | Development of NS2B-NS3 protease inhibitor that impairs Zika virus replication. Development of NS2B-NS3 protease inhibitor that impairs Zika virus replication. |
| 5 | A lesion selective albumin CTLA4Ig as a safe and effective treatment for collagen induced arthritis A lesion selective albumin CTLA4Ig as a safe and effective treatment for collagen induced arthritis |
| 6 | XPF–ERCC1 Blocker Improves the Therapeutic Efficacy of 5-FUand Oxaliplatin-Based Chemoradiotherapy in Colorectal Cancer XPF–ERCC1 Blocker Improves the Therapeutic Efficacy of 5-FUand Oxaliplatin-Based Chemoradiotherapy in Colorectal Cancer |
| 7 | A Low-Cost, Sensitive Reporter System Using Membrane-Tethered Horseradish Peroxidase for Efficient Gene Expression Analysis A Low-Cost, Sensitive Reporter System Using Membrane-Tethered Horseradish Peroxidase for Efficient Gene Expression Analysis |
| 8 | 抗PEG雙特異性抗體（mPEG × CD20）可針對並內在化PEG化奈米藥物以增強血液系統惡性腫瘤的治療效果 Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG × CD20) |
| 9 | Inhibition of gut microbial β-glucuronidase effectively prevents carcinogen-induced microbial dysbiosis and intestinal tumorigenesis. Inhibition of gut microbial β-glucuronidase effectively prevents carcinogen-induced microbial dysbiosis and intestinal tumorigenesis. |
| 10 | A universal in silico V(D)J recombination strategy for developing, humanized monoclonal antibodies A universal in silico V(D)J recombination strategy for developing, humanized monoclonal antibodies |
| 11 | Structural determination of an antibody that specifically recognizes polyethylene glycol with a terminal methoxy group Structural determination of an antibody that specifically recognizes polyethylene glycol with a terminal methoxy group |
| 12 | Structural insights into Nirmatrelvir (PF-07321332)-3C-like SARS-CoV-2 protease complexation: a ligand Gaussian accelerated molecular dynamics study. Structural insights into Nirmatrelvir (PF-07321332)-3C-like SARS-CoV-2 protease complexation: a ligand Gaussian accelerated molecular dynamics study. |
| 13 | ERCC1 Overexpression Increases Radioresistance in Colorectal Cancer Cells ERCC1 Overexpression Increases Radioresistance in Colorectal Cancer Cells |
| 14 | 轉移性結直腸癌患者化療和靶向治療中的腸道菌群組成 Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer. |
| 15 | CD44 通過 AKT下調FOXA2 促進乳腺癌轉移 CD44 Promotes Breast Cancer Metastasis through AKT-Mediated Downregulation of Nuclear FOXA2. |
| 16 | Engineering a High-Affinity Anti-Methoxy Poly(ethylene glycol) (mPEG) Antibody for Sensitive Immunosensing of mPEGylated Therapeutics and mPEG Molecules Engineering a High-Affinity Anti-Methoxy Poly(ethylene glycol) (mPEG) Antibody for Sensitive Immunosensing of mPEGylated Therapeutics and mPEG Molecules |
| 17 | Micro-PET imaging of hepatitis C virus NS3/4A protease activity using a protease-activatable retention probe Micro-PET imaging of hepatitis C virus NS3/4A protease activity using a protease-activatable retention probe |
| 18 | Structural determination of an antibody that specifically recognizes polyethylene glycol with a terminal methoxy group. Structural determination of an antibody that specifically recognizes polyethylene glycol with a terminal methoxy group. |
| 19 | Impact of anti-PEG antibody affinity on accelerated blood clearance of pegylated epoetin beta in mice. Impact of anti-PEG antibody affinity on accelerated blood clearance of pegylated epoetin beta in mice. |
| 20 | Anti-TNF Alpha Antibody Humira with pH-dependent Binding Characteristics: A constant-pH Molecular Dynamics, Gaussian Accelerated Molecular Dynamics, and In Vitro Study. Anti-TNF Alpha Antibody Humira with pH-dependent Binding Characteristics: A constant-pH Molecular Dynamics, Gaussian Accelerated Molecular Dynamics, and In Vitro Study. |
| 21 | Enhancement of tumor tropism of mPEGylated nanoparticles by anti-mPEG bispecific antibody for ovarian cancer therapy. Enhancement of tumor tropism of mPEGylated nanoparticles by anti-mPEG bispecific antibody for ovarian cancer therapy. |
| 22 | 水飛薊素作為補充劑以降低接受一線 FOLFIRI 加貝伐單抗治療的轉移性結直腸癌患者毒性的初步研究 A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab. |
| 23 | Development of a structure-based computational simulation to optimize the blocking efficacy of pro-antibodies. Development of a structure-based computational simulation to optimize the blocking efficacy of pro-antibodies. |
| 24 | Fibrinogen-Like Protein 1 Serves as an Anti-Inflammatory Agent for Collagen-Induced Arthritis Therapy in Mice Fibrinogen-Like Protein 1 Serves as an Anti-Inflammatory Agent for Collagen-Induced Arthritis Therapy in Mice |
| 25 | Development of a structure-based computational simulation to optimize the blocking efficacy of pro-antibodies (Jul, 10.1039/D1SC01748A, 2021) Development of a structure-based computational simulation to optimize the blocking efficacy of pro-antibodies (Jul, 10.1039/D1SC01748A, 2021) |
| 26 | A novel anti-tumor/anti-tumor-associated fibroblast/anti-mPEG tri-specific antibody to maximize the efficacy of mPEGylated nanomedicines against fibroblast-rich solid tumor. A novel anti-tumor/anti-tumor-associated fibroblast/anti-mPEG tri-specific antibody to maximize the efficacy of mPEGylated nanomedicines against fibroblast-rich solid tumor. |
| 27 | Selective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapy. Selective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapy. |
| 28 | Double attack strategy for leukemia using a pre-targeting bispecific, antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal, doxorubicin to enhance anti-tumor activity Double attack strategy for leukemia using a pre-targeting bispecific, antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal, doxorubicin to enhance anti-tumor activity |
| 29 | Ab Locks for Improving the Selectivity and Safety of Antibody Drugs Ab Locks for Improving the Selectivity and Safety of Antibody Drugs |
| 30 | Premature Drug Release from Polyethylene Glycol (PEG)-Coated Liposomal Doxorubicin via Formation of the Membrane Attack Complex Premature Drug Release from Polyethylene Glycol (PEG)-Coated Liposomal Doxorubicin via Formation of the Membrane Attack Complex |
| 31 | Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes. Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes. |
| 32 | 以分子模擬進行 Tsg101 UEV 蛋白與環狀胜肽抑制劑之研究 Cyclic Peptide Inhibitors of the Tsg101 UEV Protein Interactions Refined through Global Docking and Gaussian Accelerated Molecular Dynamics Simulations |
| 33 | Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer |
| 34 | Chemical Constituent of β-Glucuronidase Inhibitors from the Root of Neolitsea acuminatissima Chemical Constituent of β-Glucuronidase Inhibitors from the Root of Neolitsea acuminatissima |
| 35 | 原位直腸癌小鼠糞便菌叢移植動物模型 Gut Fecal Microbiota Transplant in a Mouse Model of Orthotopic Rectal Cancer |
| 36 | Pharmacological inhibition of bacterial β-glucuronidase prevents irinotecan-induced diarrhea without impairing its antitumor efficacy in vivo Pharmacological inhibition of bacterial β-glucuronidase prevents irinotecan-induced diarrhea without impairing its antitumor efficacy in vivo |
| 37 | Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer |
| 38 | Use of syngeneic cells expressing membrane-bound GM-CSF as an adjuvant to induce antibodies against native multi-pass transmembrane protein Use of syngeneic cells expressing membrane-bound GM-CSF as an adjuvant to induce antibodies against native multi-pass transmembrane protein |
| 39 | Use of syngeneic cells expressing membrane-bound GM-CSF as an adjuvant to induce antibodies against native multi-pass transmembrane protein. Use of syngeneic cells expressing membrane-bound GM-CSF as an adjuvant to induce antibodies against native multi-pass transmembrane protein. |
| 40 | 聚乙二醇的IgM和IgG抗體均可以改變甲氧基聚乙二醇-表觀蛋白β在小鼠中的生物活性 Both IgM and IgG Antibodies Against Polyethylene Glycol Can Alter the Biological Activity of Methoxy Polyethylene Glycol-Epoetin Beta in Mice |
| 41 | Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy |
| 42 | 茲卡病毒NS5蛋白與藥物抑制劑之分子模擬 A molecular dynamics simulation study decodes the Zika virus NS5 methyltransferase bound to SAH and RNA analogue |
| 43 | Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes |
| 44 | 3'-Hydroxy-4'-methoxy-β-methyl-β-nitrostyrene inhibits tumor growth through ROS generation and GSH depletion in lung cancer cells 3'-Hydroxy-4'-methoxy-β-methyl-β-nitrostyrene inhibits tumor growth through ROS generation and GSH depletion in lung cancer cells |
| 45 | Development of pH-sensitive cationic PEGylated solid lipid nanoparticles for selective cancer-targeted therapy Development of pH-sensitive cationic PEGylated solid lipid nanoparticles for selective cancer-targeted therapy |
| 46 | 評估轉移性大腸直腸癌病患使用FOLFIRI合併irinotecan高劑量藥物時,對於UGT1A1基因多型的前瞻性研究 Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1 genotyping in patients with metastatic colorectal cancer |
| 47 | 使用生物晶片檢測在早期復發之結腸直腸癌的臨床應用 Optimization of a multigene biochip for detection of relapsed and early relapsed colorectal cancer |
| 48 | Specific inhibition of bacterial -glucuronidase by pyrazolo[4,3-c]quinoline derivatives via a pH-dependent manner to suppress chemotherapy-induced intestinal toxicity Specific inhibition of bacterial -glucuronidase by pyrazolo[4,3-c]quinoline derivatives via a pH-dependent manner to suppress chemotherapy-induced intestinal toxicity |
| 49 | 建構可被蛋白酶活化的選擇性抗體 Selective antibody activation through protease-activated proantibodies that mask binding sites with inhibitory domains |
| 50 | 硫嘌呤誘導單層二硫化鉬奈米點螢光淬熄：應用於穀胱甘肽感測、細胞成像,與穀胱甘肽觸發藥物傳遞 6‐Mercaptopurine‐Induced Fluorescence Quenching of Monolayer MoS2 Nanodots: Applications to Glutathione Sensing, Cellular Imaging, and Glutathione‐Stimulated Drug Delivery |
| 51 | Ovatodiolide of Anisomeles indica, exerts the anti-cancer potential on pancreatic cancer cell lines through STAT3 and NF-κB regulation Ovatodiolide of Anisomeles indica, exerts the anti-cancer potential on pancreatic cancer cell lines through STAT3 and NF-κB regulation |
| 52 | 利用多生物標誌行第一期至第三期大腸直腸癌術後追蹤的前瞻性研究 A Prospective Study of Comparing Multi-Gene Biomarker Chip and Serum Carcinoembryonic Antigen in the Postoperative Surveillance for Patients with Stage I-III Colorectal Cancer |
| 53 | Using anti-poly(ethylene glycol) bioparticles for the quantitation of PEGylated nanoparticles. Using anti-poly(ethylene glycol) bioparticles for the quantitation of PEGylated nanoparticles. |
| 54 | Optimization of an Anti-poly(ethylene glycol) (anti-PEG) Cell-Based Capture System To Quantify PEG and PEGylated Molecules Optimization of an Anti-poly(ethylene glycol) (anti-PEG) Cell-Based Capture System To Quantify PEG and PEGylated Molecules |
| 55 | Quinacrine 誘導人體白血病 K562 細胞通過 P38 MAPK 引起 BCL 2 向下調控 ERK/ c-Jun 和抑制 BCL2L1 表現。 Quinacrine induces apoptosis in human leukemia K562 cells via p38 MAPK-elicited BCL2 down-regulation and suppression of ERK/c-Jun-mediated BCL2L1 expression |
| 56 | 電腦輔助藥物設計在NDM1上的應用 Inhibitor and Substrate Binding by New Delhi metallo-beta-lactamase-1: A Molecular Dynamics Studies |
| 57 | 混和量子力學與分子動力學對NDM1與抑制劑之研究 Refined Models of New Delhi metallo-beta-lactamase-1 with Inhibitors: An QM/MM Modeling Study |
| 58 | Development of Membrane-Bound GM-CSF and IL-18 as an Effective Tumor Vaccine. Development of Membrane-Bound GM-CSF and IL-18 as an Effective Tumor Vaccine. |
| 59 | 台灣眼鏡蛇磷脂酶 A2 抑制 ERK 介導 ADAM17 發展， 因而減少在人類白血病 U937 細胞中 TNF-α production 的分泌。 Taiwan cobra phospholipase A2 suppresses ERK-mediated ADAM17 maturation, thus reducing secreted TNF-α production in human leukemia U937 cells. |
| 60 | One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles |
| 61 | High-Throughput Sorting of the Highest Producing Cell via a Transiently Protein-Anchored System. High-Throughput Sorting of the Highest Producing Cell via a Transiently Protein-Anchored System. |
| 62 | Functional production of a soluble and secreted single-chain antibody by a bacterial secretion system. Functional production of a soluble and secreted single-chain antibody by a bacterial secretion system. |
| 63 | Mimicking the germinal center reaction in hybridoma cells to isolate temperature-selective anti-PEG antibodies. Mimicking the germinal center reaction in hybridoma cells to isolate temperature-selective anti-PEG antibodies. |
| 64 | The combination of the prodrugs perforin-CEBPD and perforin-granzyme B efficiently enhances the activation of caspase signaling and kills prostate cancer. The combination of the prodrugs perforin-CEBPD and perforin-granzyme B efficiently enhances the activation of caspase signaling and kills prostate cancer. |
| 65 | PET Imaging of β-Glucuronidase Activity by an Activity-Based 124I-Trapping Probe for the Personalized Glucuronide Prodrug Targeted Therapy PET Imaging of β-Glucuronidase Activity by an Activity-Based 124I-Trapping Probe for the Personalized Glucuronide Prodrug Targeted Therapy |
| 66 | 以血液中循環的腫瘤細胞作為第三期大腸癌病人接受調整性mFOLFOX化療藥物臨床反應的代替標誌 Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer |
| 67 | Sensitivity of PEGylated interferon detection by anti-polyethylene glycol (PEG) antibodies depends on PEG length. Sensitivity of PEGylated interferon detection by anti-polyethylene glycol (PEG) antibodies depends on PEG length. |
| 68 | Cross talk between p38MAPK and ERK is mediated through MAPK-mediated protein phosphatase 2A catalytic subunit α and MAPK phosphatase-1 expression in human leukemia U937 cells. Cross talk between p38MAPK and ERK is mediated through MAPK-mediated protein phosphatase 2A catalytic subunit α and MAPK phosphatase-1 expression in human leukemia U937 cells. |
| 69 | Expression of β-glucuronidase on the surface of bacteria enhances activation of glucuronide prodrugs. Expression of β-glucuronidase on the surface of bacteria enhances activation of glucuronide prodrugs. |
| 70 | 以EVI2B,ATP2A2,S100B, TM4SF3,及OLFM4做為台灣大腸直腸癌病人術後的潛在預後預測標誌 EVI2B, ATP2A2, S100B, TM4SF3, and OLFM4 as potential prognostic markers for postoperative Taiwanese colorectal cancer patients |
| 71 | 自組裝poly(epsilon-caprolactone)-g-chondroitin sulfate來包覆DOX Self-assembled poly(epsilon-caprolactone)-g-chondroitin sulfate copolymers as an intracellular doxorubicin delivery carrier against lung cancer cells |
| 72 | A regularly spaced and self-revealing protein ladder for anti-tag Western blot analysis A regularly spaced and self-revealing protein ladder for anti-tag Western blot analysis |
| 73 | [Gd(Try-TTDA)(H2O)]2-: a new MRI contrast agent for copper ion sensing. [Gd(Try-TTDA)(H2O)]2-: a new MRI contrast agent for copper ion sensing. |
| 74 | A fusion protein composed of receptor binding domain of vascular endothelial growth factor-A and constant region fragment of antibody: angiogenesis antagonistic activity. A fusion protein composed of receptor binding domain of vascular endothelial growth factor-A and constant region fragment of antibody: angiogenesis antagonistic activity. |
| 75 | A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment. A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment. |
| 76 | Enhancement of CPT-11 antitumor activity by adenovirus-mediated expression of β-glucuronidase in tumors. Enhancement of CPT-11 antitumor activity by adenovirus-mediated expression of β-glucuronidase in tumors. |
| 77 | A unique and potent protein binding nature of liposome containing polyethylenimine and polyethylene glycol: a nondisplaceable property. A unique and potent protein binding nature of liposome containing polyethylenimine and polyethylene glycol: a nondisplaceable property. |
| 78 | 發展一套多功能型抗聚乙二醇報告基因以非侵犯性造影聚乙二醇修飾探針 Development of an Universal Anti-Polyethylene Glycol Reporter Gene for Noninvasive Imaging of PEGylated Probes |
| 79 | 利用細胞及抗聚乙二醇酵素免疫分析法定量聚乙二醇 Measurement of Poly(ethylene glycol) by Cell-Based Anti-poly(ethylene glycol) ELISA |
| 80 | Endocytosis of PEGylated agents enhances cancer imaging and anticancer efficacy Endocytosis of PEGylated agents enhances cancer imaging and anticancer efficacy |
| 81 | Gene expression profiles for predicting the efficacy of the anticancer drug 5-fluorouracil in breast cancer. Gene expression profiles for predicting the efficacy of the anticancer drug 5-fluorouracil in breast cancer. |
| 82 | Sensitive Quantification of PEGylated Compounds by Second-Generation Anti-Poly(ethylene glycol) Monoclonal Antibodies. Sensitive Quantification of PEGylated Compounds by Second-Generation Anti-Poly(ethylene glycol) Monoclonal Antibodies. |
| 83 | Synthesis of poly(diallyldimethylammonium chloride)-coated Fe(3)O(4) nanoparticles for colorimetric sensing of glucose and selective extraction of thiol. Synthesis of poly(diallyldimethylammonium chloride)-coated Fe(3)O(4) nanoparticles for colorimetric sensing of glucose and selective extraction of thiol. |
| 84 | Cutting Edge: mechanical forces acting on T cells immobilized via the TCR complex can trigger TCR signaling. Cutting Edge: mechanical forces acting on T cells immobilized via the TCR complex can trigger TCR signaling. |
| 85 | A potential role for Helicobacter pylori heat shock protein 60 in gastric tumorigenesis. A potential role for Helicobacter pylori heat shock protein 60 in gastric tumorigenesis. |
| 86 | ZBRK1 acts as a metastatic suppressor by directly regulating MMP9 in cervical cancer ZBRK1 acts as a metastatic suppressor by directly regulating MMP9 in cervical cancer |
| 87 | 台灣大腸直腸癌病人MAGE家族不同表現基因輪廓 Differential Gene Expression Profile of MAGE Family in Taiwanese Patients with Colorectal Cancer |
| 88 | Simultaneous Detection of Multiple Single-Nucleotide Polymorphisms by a Simple Membrane Chip Simultaneous Detection of Multiple Single-Nucleotide Polymorphisms by a Simple Membrane Chip |
| 89 | Noninvasive Imaging of Reporter Gene Expression and Distribution In Vivo Noninvasive Imaging of Reporter Gene Expression and Distribution In Vivo |
| 90 | Targeted Herceptin–dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI Targeted Herceptin–dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI |
| 91 | GLUT1 gene is a potential hypoxic marker in colorectal cancer patients GLUT1 gene is a potential hypoxic marker in colorectal cancer patients |
| 92 | Hapten-derivatized nanoparticle targeting and imaging of gene expression by multimodality imaging systems. Hapten-derivatized nanoparticle targeting and imaging of gene expression by multimodality imaging systems. |
| 93 | GLUT1是結直腸癌病患潛在性缺氧標記 GLUT1 gene is a potential hypoxic marker in colorectal cancer patients |
| 94 | 在大氣環境下利用LIAD/ESI/MS鑑定在固態及溶液中之小分子有機物及大生物性複合物 Using Laser-Induced Acoustic Desorption/Electrospray Ionization Mass Spectrometry to Characterize Small Organic and arge Biological Compounds in the Solid State and in Solution Under Ambient Conditions. |
| 95 | 以micro-PET造影beta-glucuronidase疏水性轉換glucuronide探針 Micro-PET imaging of beta-glucuronidase activity by the hydrophobic conversion of a glucuronide probe. |
| 96 | Fluorescence turn-on detection of iodide, iodate and total iodine using fluorescein-5-isothiocyanate-modified gold nanoparticles. Fluorescence turn-on detection of iodide, iodate and total iodine using fluorescein-5-isothiocyanate-modified gold nanoparticles. |
| 97 | Ultrasensitive detection of indoleamines by combination of nanoparticle-based extraction with capillary electrophoresis/laser-induced native fluorescence Ultrasensitive detection of indoleamines by combination of nanoparticle-based extraction with capillary electrophoresis/laser-induced native fluorescence |
| 98 | Effects of Mn2+ on oligonucleotide-gold nanoparticle hybrids for colorimetric sensing of Hg2+: improving colorimetric sensitivity and accelerating color change. Effects of Mn2+ on oligonucleotide-gold nanoparticle hybrids for colorimetric sensing of Hg2+: improving colorimetric sensitivity and accelerating color change. |
| 99 | Prophylactic Proopiomelanocortin Expression Alleviates Capsaicin-Induced Neurogenic Inflammation in Rat Trachea. Prophylactic Proopiomelanocortin Expression Alleviates Capsaicin-Induced Neurogenic Inflammation in Rat Trachea. |
| 100 | Nonionic surfactant-capped gold nanoparticles for selective enrichment of aminothiols prior to CE with UV absorption detection. Nonionic surfactant-capped gold nanoparticles for selective enrichment of aminothiols prior to CE with UV absorption detection. |
| 101 | 標定活化前驅藥物之細菌以進行癌症治療 Tumor-targeting prodrug-activating bacteria for cancer therapy |
| 102 | Synthesis of Cysteine-Capped Zn(x)Cd(1)(-)(x)Se alloyed quantum dots emitting in the blue-green spectral range. Synthesis of Cysteine-Capped Zn(x)Cd(1)(-)(x)Se alloyed quantum dots emitting in the blue-green spectral range. |
| 103 | Colorimetric detection of lysozyme based on electrostatic interaction with human serum albumin-modified gold nanoparticles. Colorimetric detection of lysozyme based on electrostatic interaction with human serum albumin-modified gold nanoparticles. |
| 104 | GSTP1 313AG, MDR1 3435CC與MTHFR 677CC基因多型性與乳癌病患早期復發有顯著相關 Multiple Genetic Polymorphisms of GSTP1 313AG, MDR1 3435CC, and MTHFR 677CC highly correlated with early relapse of breast cancer patients in Taiwan. |
| 105 | Membrane-tethered proteins for basic research, imaging and therapy. Membrane-tethered proteins for basic research, imaging and therapy. |
| 106 | ERCC2 2251A>C基因多型性與高危險第二期及第三期大腸直腸癌病患之早期復發相關 ERCC2 2251A >C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients. |
| 107 | 第一至第三期大腸直腸癌病患接受根治性切除手術後持續存在循環腫瘤細胞是一項不好的癒後因子 Persistent Presence of Postoperative Circulating Tumor Cells is a Poor Prognostic Factor for Patients with Stage I–III Colorectal Cancer after Curative Resection |
| 108 | Electrospray-assisted laser desorption/ionization mass spectrometry for continuously monitoring the states of ongoing chemical reactions in organic or aqueous solution under ambient conditions. Electrospray-assisted laser desorption/ionization mass spectrometry for continuously monitoring the states of ongoing chemical reactions in organic or aqueous solution under ambient conditions. |
| 109 | Sodium hydroxide as pretreatment and fluorosurfactant-capped gold nanoparticles as sensor for the highly selective detection of cysteine. Sodium hydroxide as pretreatment and fluorosurfactant-capped gold nanoparticles as sensor for the highly selective detection of cysteine. |
| 110 | ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study. ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study. |
| 111 | Gene expression imaging by enzymatic catalysis of a fluorescent probe via membrane-anchored beta-glucuronidase. Gene expression imaging by enzymatic catalysis of a fluorescent probe via membrane-anchored beta-glucuronidase. |
| 112 | 以多重分子標記作為正常手術前後血清CEA值結直腸癌病患之預測因子 Multiple Molecular Markers as Predictors of Colorectal Cancer in Patients with Normal Perioperative Serum Carcinoembryonic Antigen Levels |
| 113 | Overexpression of Helicobacter pylori-Associated Urease mRNAs in Human Gastric Cancer Overexpression of Helicobacter pylori-Associated Urease mRNAs in Human Gastric Cancer |
| 114 | 新穎具生物活性順磁性釓金屬錯合物[Gd(DOTA-FPG)(H2O)]用以追蹤基因表現之合成與物化性探討 Synthesis and Characterization of a New Bioactivated Paramagnetic Gadolinium(III) Complex [Gd(DOTA-FPG)(H2O)] for Tracing Gene Expression |
| 115 | Prognostic Significance of Multiple Molecular Markers for Patients With Stage II Colorectal Cancer Undergoing Curative Resection. Prognostic Significance of Multiple Molecular Markers for Patients With Stage II Colorectal Cancer Undergoing Curative Resection. |
| 116 | Characterization of the chemical components on the surface of different solids with electrospray-assisted laser desorption ionization mass spectrometry Characterization of the chemical components on the surface of different solids with electrospray-assisted laser desorption ionization mass spectrometry |
| 117 | Membrane-localized activation of glucuronide prodrugs by beta-glucuronidase enzymes. Membrane-localized activation of glucuronide prodrugs by beta-glucuronidase enzymes. |
| 118 | Combination of Tumor Site-Located CTL-Associated Antigen-4 Blockade and Systemic Regulatory T-Cell Depletion InducesTumor-Destructive Immune Responses. Combination of Tumor Site-Located CTL-Associated Antigen-4 Blockade and Systemic Regulatory T-Cell Depletion InducesTumor-Destructive Immune Responses. |
| 119 | Phosphate-Modified TiO2 Nanoparticles for Selective Detection of Dopamine, Levodopa, Adrenaline, and Catechol Based on Fluorescence Quenching. Phosphate-Modified TiO2 Nanoparticles for Selective Detection of Dopamine, Levodopa, Adrenaline, and Catechol Based on Fluorescence Quenching. |
| 120 | Fatty acid metabolism pathway play an important role in carcinogenesis of human colorectal cancers by Microarray-Bioinformatics analysis. Fatty acid metabolism pathway play an important role in carcinogenesis of human colorectal cancers by Microarray-Bioinformatics analysis. |
| 121 | 探討人類TCF4在大腸和血癌細胞之衛星不穩定現況 Genetic and cellular characterizations of human TCF4 with microsatellite instability in colon cancer and leukemia cell lines |
| 122 | A membrane antibody receptor for noninvasive imaging of gene expression. A membrane antibody receptor for noninvasive imaging of gene expression. |
| 123 | Combination Cancer Therapy by Hapten-Targeted Produrg-Activating Enzymes and Cytokines Combination Cancer Therapy by Hapten-Targeted Produrg-Activating Enzymes and Cytokines |
| 124 | Membrane-localized activation of glucuronide prodrugs by beta-glucuronidase enzymes Membrane-localized activation of glucuronide prodrugs by beta-glucuronidase enzymes |
| 125 | 分子偵測胃癌病人周邊血液之循環腫瘤細胞：評估其預後意義 Molecular detection of disseminated tumor cells in the peripheral blood of patients with gastric cancer: evaluation of their prognostic significance |
| 126 | 結腸直腸腺瘤腫瘤形成的分子機制：與K-ras腫瘤基因活化的關連性 Molecular mechanisms underlying the tumorigenesis of colorectal adenomas: correlation to activated K-ras oncogene. |
| 127 | 台灣非小細胞肺癌在p53基因有高頻率序列位移突變 High frequency of frameshift mutation on p53 gene in Taiwanese with non small cell lung cancer. |
| 128 | 擷血液中cMet訊息核酸的過度表現與非小細胞肺癌之Nstage與早期復發有重要統計關係 Overexpression of Circulating c-Met mRNA is Significantly Correlated with Nodal Stage and Early Recurrence in Non-Small Cell Lung Cancer. |
| 129 | 以cDNA microarray 分析大腸癌癌化的過度表現基因 Analysis of progressively overexpressed genes in tumorigenesis of colorectal cancers using cDNA microarray. |
| 130 | 利用基因晶片來偵測循環性癌細胞的K-ras Detection of circulating cancer cells with K-ras oncogene using membrane array. |
| 131 | 以單株抗體定量聚乙二醇修飾之蛋白質 酯質體 和奈米粒子 Monoclonal antibody-based quantitation of poly(ethylene glycol-derivatized proteins, liposomes, and nanoparticles |
| 132 | Detection of circulating cancer cells with K-ras oncogene using membrane array Detection of circulating cancer cells with K-ras oncogene using membrane array |
| 133 | 以分子偵測大腸直腸病患血清中APC, K-RAS, P53基因突變作為循環標記 Molecular Detection of APC, K-ras, and p53 Mutations in the Serum of Colorectal Cancer Patients as Circulating Biomarkers |
| 134 | Hapten-directed targeting to single-chain antibody receptors. Hapten-directed targeting to single-chain antibody receptors. |
| 135 | APC, c-met與 p53基因在胃癌病人腫瘤組織與血清中變異分析 Alterations of APC, c-met, and p53 Genes in Tumor Tissue and Serum of Patients with Gastric Cancers |
| 136 | Anti-4-1BB-based immunotherapy for autoimmune diabetes: lessons from a transgenic non-obese diabetic (NOD) model. Anti-4-1BB-based immunotherapy for autoimmune diabetes: lessons from a transgenic non-obese diabetic (NOD) model. |
| 137 | Sensitive quantitation of poly(ethylene glycol)-modified proteins Sensitive quantitation of poly(ethylene glycol)-modified proteins |
| 138 | Potentiation of antitumor immunity by antibody-directed enzyme prodrug therapy Potentiation of antitumor immunity by antibody-directed enzyme prodrug therapy |
| 139 | Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. |
| 140 | Bystander killing of tumor cells byantibody-targeted enzymatic activation of a glucuronide prodrug Bystander killing of tumor cells byantibody-targeted enzymatic activation of a glucuronide prodrug. |
| 141 | Characterization of an antineoplastic glucuronide prodrug Characterization of an antineoplastic glucuronide prodrug. |
| 142 | Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM |
Project
| NO |
YEAR — Source — No — Type
Project Name
|
Duration |
|---|---|---|
| 1 |
114 — N 國科會(原科技部) — NSTC112-2320-B-037-011-MY3 — 1 個人型
建構弱酸可斷裂之雙功能抗體(αTfR-pH linker-αAβ)以運送抗體藥穿透血腦障壁並改善阿茲海默症的治療療效(3/3)( )
|
2025/08/01 ~ 2026/07/31 |
| 2 |
113 — KT 高醫清大 — KT113P004 — 1 個人型
以X光晶體繞射法及冷凍電顯探討雙價抗聚乙二醇之三功能抗體(αmPEG×αPEG×αHER2)與聚乙二醇微脂體藥物 (PLD)的結合情形(Study on the Binding of Bivalent Anti-PEG Trispecific Antibody (ɑmPEG×ɑPEG×ɑHER2) and PEGylated liposomal doxorubicin (PLD) by X-ray Crystallography and cryo-EM)
|
2024/01/01 ~ 2024/12/31 |
| 3 |
113 — N 國科會(原科技部) — NSTC112-2320-B-037-011-MY3 — 1 個人型
建構弱酸可斷裂之雙功能抗體(αTfR-pH linker-αAβ)以運送抗體藥穿透血腦障壁並改善阿茲海默症的治療療效(2/3)( )
|
2024/08/01 ~ 2026/07/31 |
| 4 |
113 — TC 研究中心計畫 — KMU-TC113A03 — 6 研究中心
KMU-113年度校級研究中心計畫-學術-新藥開發暨價創研究中心( )
|
2024/01/01 ~ 2024/12/31 |
| 5 |
113 — TC 研究中心計畫 — KMU-TC113A03-2 — 6 研究中心
【整合團隊計畫】以不死化B細胞抗體平台開發全人類診斷及治療性抗體( )
|
2024/01/01 ~ 2024/12/31 |
| 6 |
112 — DK 前瞻重點(原校院) — KMU-DK(B)113001-1 —
延長白斑病患 B 細胞 之培養壽命並以單一 B 細胞分離定序具抗 黑色素細胞及抗角質 細胞特性之抗體序列( )
|
2024/01/01 ~ 2024/12/31 |
| 7 |
112 — KT 高醫清大 — KT112P002 — 1 個人型
結合前驅抗體電腦模擬系統和蛋白質結構測定技術於優化萬能抗體鎖平台以提升抗體藥物安全性( )
|
2023/01/01 ~ 2023/12/31 |
| 8 |
112 — N 國科會(原科技部) — NSTC112-2320-B-037-011-MY3 — 1 個人型
建構弱酸可斷裂之雙功能抗體(αTfR-pH linker-αAβ)以運送抗體藥穿透血腦障壁並改善阿茲海默症的治療療效(1/3)( )
|
2023/08/01 ~ 2026/07/31 |
| 9 |
112 — N 國科會(原科技部) — NSTC112-2124-M-037-001 — 1 個人型
開發具雙價抗聚乙二醇之三功能抗體(mPEG X PEG X HER2)一步武裝聚乙二醇奈米藥物以提升其活體內結合穩定度及治療效果(2/3)( )
|
2023/08/01 ~ 2024/07/31 |
| 10 |
112 — TC 研究中心計畫 — KMU-TC112A03 — 6 研究中心
KMU-112年度校級研究中心計畫-學術-新藥開發暨價創研究中心( )
|
2023/01/01 ~ 2023/12/31 |
| 11 |
112 — TC 研究中心計畫 — KMU-TC112A03-4 — 6 研究中心
【獎勵補助整合型計畫】-開發具雙價抗聚乙二醇之三功能抗體(mPEG X PEG X HER2)一步武裝聚乙二醇奈米藥物以提升其活體內結合穩定度及治療效果(國科會奈米科技創新應用計畫)( )
|
2023/01/01 ~ 2023/12/31 |
| 12 |
112 — Z 大專學生研究計畫及博士後 — NSTC112-2811-B-037-004 — 9 博士後研究員
博士級研究人員--何愷文( )
|
2023/08/01 ~ 2024/07/31 |
| 13 |
112 — Z 大專學生研究計畫及博士後 — NSTC112-2811-M-037-006 — 9 博士後研究員
博士級研究人員--廖俊閔( )
|
2023/08/01 ~ 2024/07/31 |
| 14 |
111 — DK 前瞻重點(原校院) — KMU-DK(B)112001-3 — 2 整合型
發展具氧化還原活性之含氮雜焓碳烯金屬醯胺錯合物及其光動力療法的應用( )
|
2023/01/01 ~ 2023/12/31 |
| 15 |
111 — N 國科會(原科技部) — MOST109-2320-B-037-010-MY3 — 1 個人型
開發具選擇性活化之免疫檢查點前驅抗體(pro-anti-CTLA-4/PD-1) 以提升腫瘤治療效果及藥物安全性(3/3)( )
|
2022/08/01 ~ 2023/07/31 |
| 16 |
111 — N 國科會(原科技部) — MOST111-2124-M-037-001 — 2 整合型
開發具雙價抗聚乙二醇之三功能抗體(mPEG X PEG X HER2)一步武裝聚乙二醇奈米藥物以提升其活體內結合穩定度及治療效果(1/3)( )
|
2022/08/01 ~ 2023/07/31 |
| 17 |
111 — NF 國科會鼓勵企業參與培育博士研究生試辦方案 — NSTC109-2320-B-037-010-MY3 —
國科會補助企業參與培育博士研究生試辦方案博士研究生獎學金-台灣醣聯生技醫藥股份有限公司( )
|
2022/08/01 ~ 2023/07/31 |
| 18 |
111 — Z 大專學生研究計畫及博士後 — MOST111-2811-M-037-003 — 9 博士後研究員
博士級研究人員--廖俊閔( )
|
2022/08/01 ~ 2023/07/31 |
| 19 |
111 — Z 大專學生研究計畫及博士後 — NSTC112-2813-C-037-019-B — 8 大專學生研究計畫
112年度大專學生研究計畫-許亞瑄(生物3)( )
|
2023/07/01 ~ 2024/02/29 |
| 20 |
110 — DK 前瞻重點(原校院) — KMU-DK(B)111001-2 —
雙價抗聚乙二醇之三功能抗體(PEG2×HER2)一步武裝於奈米微脂體藥物以提升其活體內 藥物穩定度及治療效果( )
|
2022/01/01 ~ 2022/12/31 |
| 21 |
110 — N 國科會(原科技部) — MOST109-2320-B-037-010-MY3 — 1 個人型
開發具選擇性活化之免疫檢查點前驅抗體(pro-anti-CTLA-4/PD-1) 以提升腫瘤治療效果及藥物安全性(2/3)( )
|
2021/08/01 ~ 2023/07/31 |
| 22 |
110 — N 國科會(原科技部) — MOST110-2627-M-037-001 — 2 整合型
以電腦計算輔以X光晶體繞射技術及冷凍電顯精準前驅抗體基因工程全面性提升抗體藥物疾病區域選擇性並降低副作用(2/2)( )
|
2021/11/01 ~ 2022/10/31 |
| 23 |
110 — NF 國科會鼓勵企業參與培育博士研究生試辦方案 — MOST109-2320-B-037-010-MY3 —
科技部補助企業參與培育博士研究生試辦方案博士研究生獎學金-台灣醣聯生技醫藥股份有限公司( )
|
2021/08/01 ~ 2022/07/31 |
| 24 |
110 — NK 高醫-中山合作計畫 — — 2 整合型
酸鹼值可調控TfR Fab × Aβ Ab 雙功能抗體其提升對血腦障壁穿透能力( )
|
2021/01/01 ~ 2021/12/31 |
| 25 |
110 — NK 高醫-中山合作計畫 — — 2 整合型
建構酸鹼值可調控TfRFab × Aβ Ab 雙功能抗體以提升對血腦障壁( )
|
2021/01/01 ~ 2021/12/31 |
| 26 |
110 — TC 研究中心計畫 — KMU-TC111A03-0 —
KMU-111年度校級研究中心計畫-學術-新藥開發暨價創研究中心( )
|
2022/01/01 ~ 2022/12/31 |
| 27 |
110 — TC 研究中心計畫 — KMU-TC111A03-5 —
建構弱酸可斷裂雙功能抗體平台以運送抗體藥穿透血腦障壁入大腦( )
|
2022/01/01 ~ 2022/12/31 |
| 28 |
110 — TC 研究中心計畫 — KMUTC111IFSP02 — 2 整合型
111年度校級學術研究中心跨域旗艦型計畫-新藥開發暨價創研究中心(以萬能抗體鎖提升抗體藥物之腫瘤選擇性，並輔以腫瘤微環境免疫活化劑全面性提升癌症免疫療法之治療效率並降低副作用)(Drug Development and Value Creation Research Center (Enhancing the tumor selectivity of antibody drugs by using universal antibody lock and combine with immunomodulator for comprehensively improving the therapeutic efficacy and reducing side effects of cancer immune therapy))
|
2022/01/01 ~ 2022/12/31 |
| 29 |
110 — Z 大專學生研究計畫及博士後 — MOST111-2813-C-037-032-B — 8 大專學生研究計畫
111年度大專學生研究計畫-游翔臻(生物3)( )
|
2022/07/01 ~ 2023/02/28 |
| 30 |
109 — DK 前瞻重點(原校院) — KMU-DK(B)110004-2 —
測試具不同蛋白酶活化特性之前驅抗體(pro-αEGFR Ab)的蛋白酶活化效率及大腸癌治療效果( )
|
2021/01/01 ~ 2021/12/31 |
| 31 |
109 — N 國科會(原科技部) — MOST107-2320-B-037-024-MY3 — 1 個人型
利用空間性屏蔽抗體鎖建構前驅抗體(pro-Humira)以降低抗藥抗體對其半衰期與療效之干擾(3/3)( )
|
2020/08/01 ~ 2021/07/31 |
| 32 |
109 — N 國科會(原科技部) — MOST109-2320-B-037-010-MY3 — 1 個人型
開發具選擇性活化之免疫檢查點前驅抗體(pro-anti-CTLA-4/PD-1) 以提升腫瘤治療效果及藥物安全性(1/3)( )
|
2020/08/01 ~ 2023/07/31 |
| 33 |
109 — N 國科會(原科技部) — MOST109-2627-M-037-001 — 2 整合型
以電腦計算輔以X光晶體繞射技術及冷凍電顯精準前驅抗體基因工程全面性提升抗體藥物疾病區域選擇性並降低副作用(1/2)( )
|
2020/11/01 ~ 2021/10/31 |
| 34 |
109 — NF 國科會鼓勵企業參與培育博士研究生試辦方案 — MOST109-2320-B-037-010-MY3 —
科技部補助企業參與培育博士研究生試辦方案博士研究生獎學金-台灣醣聯生技醫藥股份有限公司( )
|
2020/09/01 ~ 2021/07/31 |
| 35 |
109 — TC 研究中心計畫 — KMU-TC109A03-0 —
KMU-202001校級研究中心計畫-學術-新藥開發暨價創研究中心( )
|
2021/01/01 ~ 2021/12/31 |
| 36 |
109 — TC 研究中心計畫 — KMU-TC109A03-3 —
總計畫、開發人類化雙功能抗體(mPEG×CD20, CD3×CD20)賦予奈米藥物、造影劑與免疫細胞之腫瘤專一性，以提供淋巴癌之標靶造影與治療( )
|
2021/01/01 ~ 2021/12/31 |
| 37 |
109 — TC 研究中心計畫 — KMU-TC109PR-D951 —
KMU109校級研究中心收費平台收入運用-新藥開發暨價創研究中心( )
|
2020/08/01 ~ 2021/07/31 |
| 38 |
109 — TC 研究中心計畫 — KMU-TC109TA-D951 —
KMU109-TA03技轉權利金-新藥開發暨價創研究中心( )
|
2020/08/01 ~ 2021/07/31 |
| 39 |
109 — Z 大專學生研究計畫及博士後 — MOST109-2811-B-037-523 — 9 博士後研究員
博士後研究員--陳怡如( )
|
2020/08/01 ~ 2021/07/31 |
| 40 |
109 — Z 大專學生研究計畫及博士後 — MOST110-2813-C-037-014-B — 8 大專學生研究計畫
110年度大專學生研究計畫-趙玹(生物3)( )
|
2021/07/01 ~ 2022/02/28 |
| 41 |
108 — DK 前瞻重點(原校院) — KMU-DK(整)109001~1 —
探討Hinge Yervoy 於人類 CTLA-4基因轉殖鼠中之療效、藥物動力學與副作用的影響( )
|
2020/01/01 ~ 2020/12/31 |
| 42 |
108 — I 國衛院 — NHRI-EX109-10729EI —
開發蛋白脢可切之雙功能抗體(mPEG×TfR)以標定聚乙二醇-奈米藥物通過血腦障壁並增加其釋放( )
|
2020/01/01 ~ 2020/12/31 |
| 43 |
108 — N 國科會(原科技部) — MOST107-2320-B-037-024-MY3 — 1 個人型
利用空間性屏蔽抗體鎖建構前驅抗體(pro-Humira)以降低抗藥抗體對其半衰期與療效之干擾(2/3)( )
|
2019/08/01 ~ 2021/07/31 |
| 44 |
108 — NK 高醫-中山合作計畫 — NSYSUKMU108-I008-1 — 2 整合型
以全人抗體3D結構資料庫針對標靶蛋白(PD1)的抗原結合位(epitope)篩選出最佳化中和性治療抗體( )
|
2019/01/01 ~ 2019/12/31 |
| 45 |
108 — TC 研究中心計畫 — KMU-TC108A03-0 — 6 研究中心
KMU-108校級研究中心計畫-學術-新藥開發暨價創研究中心( )
|
2019/08/01 ~ 2020/07/31 |
| 46 |
108 — TC 研究中心計畫 — KMU-TC108A03-3 —
可提高所有抗體藥物選擇性的抗體鎖平台之產業服務與推廣( )
|
2019/08/01 ~ 2020/07/31 |
| 47 |
108 — X 高奇合作計畫 — 109CM-KMU-14 —
執行及推展奇美高醫建教研究合作計畫案( )
|
2020/05/01 ~ 2021/04/30 |
| 48 |
108 — Z 大專學生研究計畫及博士後 — MOST108-2811-B-037-523 — 9 博士後研究員
博士後研究員-陳怡如( )
|
2019/08/01 ~ 2020/07/31 |
| 49 |
108 — Z 大專學生研究計畫及博士後 — MOST109-2813-C-037-056-B — 8 大專學生研究計畫
109年度大專學生研究計畫-林敬軒(生物3)( )
|
2020/07/01 ~ 2021/02/28 |
| 50 |
107 — DK 前瞻重點(原校院) — KMU-DK108002 —
開發具CD20標靶內吞性微脂體(CD20/GSL)以提高化療藥物(9-胺基喜樹鹼)對淋巴癌之療效( )
|
2018/08/01 ~ 2019/07/31 |
| 51 |
107 — I 國衛院 — NHRI-EX108-10729EI —
開發蛋白脢可切之雙功能抗體(mPEG×TfR)以標定聚乙二醇-奈米藥物通過血腦障壁並增加其釋放(Targeted mPEG-nanoparticle release into blood-brain barrier by a protease cleavable BsAb (mPEG×TfR))
|
2019/01/01 ~ 2019/12/31 |
| 52 |
107 — N 國科會(原科技部) — MOST107-2320-B-037-024-MY3 — 1 個人型
利用空間性屏蔽抗體鎖建構前驅抗體(pro-Humira)以降低抗藥抗體對其半衰期與療效之干擾(1/3)( )
|
2018/08/01 ~ 2021/07/31 |
| 53 |
107 — X 高奇合作計畫 — 108CM-KMU-14 —
執行及推展奇美高醫建教研究合作計劃案( )
|
2019/05/01 ~ 2020/04/30 |
| 54 |
107 — Z 大專學生研究計畫及博士後 — MOST107-2811-B-037-008 — 9 博士後研究員
博士後研究員--謝元欽( )
|
2018/08/01 ~ 2019/07/31 |
| 55 |
107 — Z 大專學生研究計畫及博士後 — MOST107-2811-B-037-522 — 9 博士後研究員
博士後研究員--陳怡如( )
|
2018/09/01 ~ 2019/07/31 |
| 56 |
107 — Z 大專學生研究計畫及博士後 — MOST108-2813-C-037-030-B — 8 大專學生研究計畫
108年度大專學生研究計畫-李子瑜(生物3)( )
|
2019/07/01 ~ 2020/02/29 |
| 57 |
106 — DK 前瞻重點(原校院) — KMU-DK107001 —
開發具蛋白酶活化特性之前驅抗體(Hinge anti PD-1 Ab)以增加癌症免疫治療選擇性並降低副作用( )
|
2017/08/01 ~ 2018/07/31 |
| 58 |
106 — I 國衛院 — NHRI-EX107-10729EI —
開發蛋白脢可切之雙功能抗體(mPEGxTfR)以標定聚乙二醇-奈米藥物通過血腦障壁並增加其釋放( )
|
2018/01/01 ~ 2018/12/31 |
| 59 |
106 — N 國科會(原科技部) — MOST106-2632-B-037-003 — 2 整合型
以人類化雙功能抗體一步武裝微脂體、免疫細胞與奈米造影劑以開發淋巴癌之標靶造影與治療( )
|
2017/08/01 ~ 2018/10/31 |
| 60 |
106 — X 高奇合作計畫 — 107CM-KMU-14 —
執行及推展奇美高醫建教研究合作計畫案( )
|
2018/05/01 ~ 2019/04/30 |
| 61 |
105 — DT 攻頂(高醫) — KMU-DT106003 —
開發具蛋白脢活化特性之前驅抗腫瘤壞死因子抗體(pro-Remicade/Humira)以增加類風濕性關節炎治療選擇性並降低副作用( )
|
2016/08/01 ~ 2017/07/31 |
| 62 |
105 — OX 其他單位(非研究) — GRC106TSPA01 —
以電腦進行人類V(D)J抗體重組及以特定抗原結構對街(Docking)人類抗體庫篩選與開發人類抗體藥物研發計畫( )
|
2017/03/01 ~ 2017/12/31 |
| 63 |
105 — TP 頂尖計畫(高醫) — KMU-TP105C00 —
總計畫、以創新生物標記與生技藥物輔助疾病診斷及治療之研發( )
|
2016/11/01 ~ 2017/10/31 |
| 64 |
105 — TP 頂尖計畫(高醫) — KMU-TP105C07 —
子計畫七、以大腸癌不死化B細胞抗體庫，開發對抗大腸癌之診斷及治療性抗體( )
|
2016/11/01 ~ 2017/10/31 |
| 65 |
105 — TP 頂尖計畫(高醫) — KMU-TP105C15 —
平台五、全人類抗體藥物篩選平台(不死化B細胞)( )
|
2016/11/01 ~ 2017/10/31 |
| 66 |
105 — TP 頂尖計畫(高醫) — KMU-TP105C17 —
平台七、穩定表現報導基因細胞造影平台(螢光/GFP,RFP、冷光、遠紅光)( )
|
2016/11/01 ~ 2017/10/31 |
| 67 |
105 — TP 頂尖計畫(高醫) — KMU-TP105C18 —
平台八、各式PEG-藥物定量平台( )
|
2016/11/01 ~ 2017/10/31 |
| 68 |
105 — Z 大專學生研究計畫及博士後 — MOST106-2813-C-037-022-B — 8 大專學生研究計畫
106年度大專學生研究計畫-蘇家儀(生技3)( )
|
2017/07/01 ~ 2018/02/28 |
| 69 |
104 — DT 攻頂(高醫) — KMU-DT105003 —
開發具蛋白脢活化特性之前驅抗腫瘤壞死因子抗體(pro-Remicade/Humira)以增加類風濕性關節炎治療選擇性並降低副作用( )
|
2015/08/01 ~ 2016/07/31 |
| 70 |
104 — N 國科會(原科技部) — MOST105-2325-B-037-002 — A 國家型
以抗聚乙二醇雙功能抗體非共價鍵修飾聚乙二醇-奈米分子以進行腫瘤標的治療(3/3)( )
|
2016/05/01 ~ 2017/04/30 |
| 71 |
104 — TP 頂尖計畫(高醫) — KMU-TP104C00 —
總計畫、以大腸癌為標的輔助診斷、療效評估與藥物之生物標記與生技藥物研發( )
|
2015/10/01 ~ 2016/09/30 |
| 72 |
104 — TP 頂尖計畫(高醫) — KMU-TP104C05 —
子計畫五、以大腸癌不死化B細胞抗體庫，開發對抗大腸癌之診斷及治療性抗體( )
|
2015/10/01 ~ 2016/09/30 |
| 73 |
104 — TP 頂尖計畫(高醫) — KMU-TP104C07 —
平台二、中和性抗體開發平台( )
|
2015/10/01 ~ 2016/09/30 |
| 74 |
104 — TP 頂尖計畫(高醫) — KMU-TP104C09 —
平台四、不死化B細胞(Immortalized B cell)抗體生產平台( )
|
2015/10/01 ~ 2016/09/30 |
| 75 |
104 — TP 頂尖計畫(高醫) — KMU-TP104C10 —
平台五、穩定表現遠紅光蛋白細胞造影平台( )
|
2015/10/01 ~ 2016/09/30 |
| 76 |
104 — TP 頂尖計畫(高醫) — KMU-TP104D06 —
子計畫六、開發可專一性辨認人類陰電脂蛋白(L5)抗體，以診斷、預防與治療心血管疾病( )
|
2015/10/01 ~ 2016/09/30 |
| 77 |
104 — Z 大專學生研究計畫及博士後 — MOST105-2815-C-037-031-B — 8 大專學生研究計畫
105年度大專學生研究計畫-劉思媛(生物3)( )
|
2016/07/01 ~ 2017/02/28 |
| 78 |
104 — Z 大專學生研究計畫及博士後 — MOST105-2815-C-037-039-B — 8 大專學生研究計畫
105年度大專學生研究計畫-林宜嫺(生物3)( )
|
2016/07/01 ~ 2017/02/28 |
| 79 |
103 — NK 高醫-中山合作計畫 — NSYSUKMU103-I003 — 2 整合型
胰臟癌的早期診斷之建立、抗體藥物的研發及動物模式之研究( )
|
2014/01/01 ~ 2014/12/31 |
| 80 |
103 — NK 高醫-中山合作計畫 — NSYSUKMU103-I003-3 — 2 整合型
建立不死化B細胞抗體庫(Immortalized-B cell antibody library)以開發對抗胰臟癌之診斷及治療性抗體( )
|
2014/01/01 ~ 2014/12/31 |
| 81 |
103 — N 國科會(原科技部) — MOST104-2325-B-037-003 — A 國家型
以抗聚乙二醇雙功能抗體非共價鍵修飾聚乙二醇-奈米分子以進行腫瘤標的治療(2/3)( )
|
2015/05/01 ~ 2016/04/30 |
| 82 |
103 — TP 頂尖計畫(高醫) — KMU-TP103C00 —
Development of biomarkers and biotech drug for the early diagnosis, prediction, prognosis and tailored therapy for colorectal cancers(Development of biomarkers and biotech drug for the early diagnosis, prediction, prognosis and tailored therapy for colorectal cancers)
|
2014/08/01 ~ 2015/07/31 |
| 83 |
103 — TP 頂尖計畫(高醫) — KMU-TP103C01 —
The platform to develop therapeutic and diagnostic antibodies(The platform to develop therapeutic and diagnostic antibodies)
|
2014/08/01 ~ 2015/07/31 |
| 84 |
103 — TP 頂尖計畫(高醫) — KMU-TP103C11 —
Development of specific antibody from tumor-infiltrating B lymphocytes (TIL-B) for colorectal cancer diagnosis and targeted therapy(Development of specific antibody from tumor-infiltrating B lymphocytes (TIL-B) for colorectal cancer diagnosis and targeted therapy)
|
2014/08/01 ~ 2015/07/31 |
| 85 |
103 — TP 頂尖計畫(高醫) — KMU-TP103H10 —
開發降低化療引起腸道毒性之eβG專一性抑制劑篩選平台( )
|
2014/08/01 ~ 2015/07/31 |
| 86 |
103 — Z 大專學生研究計畫及博士後 — 104-2815-C-037-005-B — 8 大專學生研究計畫
104年度大專學生研究計畫-喻曼婷(生物3)( )
|
2015/07/01 ~ 2016/02/29 |
| 87 |
103 — Z 大專學生研究計畫及博士後 — 104-2815-C-037-017-B — 8 大專學生研究計畫
104年度大專學生研究計畫-陳乃綺(生物3)( )
|
2015/07/01 ~ 2016/02/29 |
| 88 |
102 — DT 攻頂(高醫) — KMU-DT103005 —
開發具蛋白脢活化特性之前驅抗腫瘤壞死因子抗體(pro-Remicade/Humira)以增加類風濕性關節炎治療選擇性並降低副作用( )
|
2014/05/01 ~ 2015/07/31 |
| 89 |
102 — N 國科會(原科技部) — NSC102-2321-B-037-001 — 1 個人型
利用環境益生菌分泌對斑蚊幼蟲具選擇毒性之蛋白以控制登革熱之傳播(3/3)( )
|
2013/08/01 ~ 2014/07/31 |
| 90 |
102 — N 國科會(原科技部) — MOST103-2325-B-037-007 — A 國家型
以抗聚乙二醇雙功能抗體非共價鍵修飾聚乙二醇-奈米分子以進行腫瘤標的治療(1/3)( )
|
2014/05/01 ~ 2015/04/30 |
| 91 |
102 — Z 大專學生研究計畫及博士後 — NSC102-2811-B-037-012 — 9 博士後研究員
博士後研究員-黃建喬( )
|
2013/08/01 ~ 2014/07/31 |
| 92 |
102 — NK 高醫-中山合作計畫 — NSYSUKMU102-P035 — 1 個人型
開發治療人類大腸癌的肝癌衍生生長因子抗體(The therapeutic strategy of anti-HDGF antibody for human colortctal cancer)
|
2013/01/01 ~ 2013/12/31 |
| 93 |
101 — N 國科會(原科技部) — NSC101-2321-B-037-001 — 1 個人型
利用環境益生菌分泌對斑蚊幼蟲具選擇毒性之蛋白以控制登革熱之傳播(2/3)( )
|
2012/08/01 ~ 2013/07/31 |
| 94 |
101 — N 國科會(原科技部) — NSC102-2325-B-037-001 — A 國家型
以雙功能標靶抗體(臨床抗體藥物人類化抗聚乙二醇單鏈抗體)主動吸引聚乙二醇修飾藥物以產生加成性雙重攻擊之抗癌療效(3/3)( )
|
2013/05/01 ~ 2014/07/31 |
| 95 |
101 — Z 大專學生研究計畫及博士後 — 102-2815-C-037-011-B — 8 大專學生研究計畫
102年度大專學生研究計畫-陳彥豪(生技3)( )
|
2013/07/01 ~ 2014/02/28 |
| 96 |
100 — N 國科會(原科技部) — NSC100-2321-B-037-006 — 1 個人型
利用環境益生菌分泌對斑蚊幼蟲具選擇毒性之蛋白以控制登革熱之傳播(1/3)( )
|
2011/08/01 ~ 2012/07/31 |
| 97 |
100 — N 國科會(原科技部) — NSC101-2325-B-037-001 — A 國家型
以雙功能標靶抗體(臨床抗體藥物-人類化抗聚乙二醇單鏈抗體)主動吸引聚乙二醇修飾藥物以產生加成性雙重攻擊之抗癌療效(2/3)( )
|
2012/05/01 ~ 2013/04/30 |
| 98 |
100 — Z 大專學生研究計畫及博士後 — NSC101-2815-C-037-026-B — 8 大專學生研究計畫
101年度大專學生參與專題研究計畫--朱珮瑜(生物系3)( )
|
2012/07/01 ~ 2013/02/28 |
| 99 |
099 — H 衛福部 — DOH100-TD-N-111-010 —
可定量任何聚乙二醇-奈米分子平台之商品化與產業化轉譯研究( )
|
2011/06/01 ~ 2012/05/31 |
| 100 |
099 — N 國科會(原科技部) — NSC100-2325-B-037-001 — 1 個人型
以雙功能標靶抗體(臨床抗體藥物*人類化抗聚乙二醇單鏈抗體)主動吸引聚乙二醇修飾藥物以產生加成性雙重攻繫之抗癌療效(1/3)( )
|
2011/05/01 ~ 2012/04/30 |
| 101 |
099 — Z 大專學生研究計畫及博士後 — NSC100-2815-C-037-013-B — 8 大專學生研究計畫
100年度大專學生參與專題研究計畫--李姿瑩(生物3)( )
|
2011/07/01 ~ 2012/02/01 |
| 102 |
098 — N 國科會(原科技部) — NSC96-2320-B-037-010-MY3 — 1 個人型
創新疾病易感性基因型分析技術的研發(3/3)( )
|
2009/08/01 ~ 2010/07/31 |
| 103 |
098 — N 國科會(原科技部) — NSC99-3112-B-037-001 — 1 個人型
以膜抗體當報告基因-活體內造影基因表現專一性、自體免疫病程與胰島細胞移植存活情形(2/2)( )
|
2010/05/01 ~ 2011/07/31 |
| 104 |
098 — Q 新聘教師計畫(校內) — KMU-Q099001B —
結合結構電腦模擬以輔助抗體人類化之基因工程技術(Computing Antibody Engineering)( )
|
2010/02/01 ~ 2010/12/31 |
| 105 |
098 — Z 大專學生研究計畫及博士後 — NSC98-2811-B-037-016 — 9 博士後研究員
博士後研究--翁永豪( )
|
2009/08/01 ~ 2010/07/31 |
| 106 |
098 — Z 大專學生研究計畫及博士後 — NSC99-2815-C-037-022-B — 8 大專學生研究計畫
99年度大專學生參與專題研究計畫-呂韻綺( )
|
2010/07/01 ~ 2011/02/28 |
| 107 |
097 — G 農業部(原農委會) — 98農科-1.1.5-衛-H2 — 1 個人型
構築哺乳類細胞株表達A型流感病毒NP蛋白抗原( )
|
2009/04/10 ~ 2009/12/10 |
| 108 |
097 — G 農業部(原農委會) — 98農科-9.2.4-衛-H1 — 1 個人型
構築豬瘟及第二型豬環狀病毒DNA疫苗pE2-C3及pORF2-C3質體( )
|
2009/04/10 ~ 2009/12/10 |
| 109 |
097 — I 國衛院 — NHRI-EX98-9624SI — 1 個人型
以抗拒乙二醇單鏈Fab膜抗體當報告基因以造影基因於活體內的表現( )
|
2009/01/01 ~ 2009/12/31 |
| 110 |
097 — N 國科會(原科技部) — NSC96-2320-B-037-010-MY3 — 1 個人型
創新疾病易感性基因型分析技術的研發(2/3)( )
|
2008/08/01 ~ 2010/07/31 |
| 111 |
097 — N 國科會(原科技部) — NSC98-3112-B-037-001 — 1 個人型
以膜抗體當報告基因-活體內造影基因表現專一性、自體免疫病程與胰島細胞移植存活情形(1/2)( )
|
2009/05/01 ~ 2010/04/30 |
| 112 |
097 — U 教育部 — —
98生物及醫學科技人才培育先導型計畫( )
|
2009/01/01 ~ 2009/12/31 |
| 113 |
097 — Z 大專學生研究計畫及博士後 — NSC97-2811-B-037-006 — 9 博士後研究員
博士後研究--鄭秋敏( )
|
2008/08/01 ~ 2009/07/31 |
| 114 |
097 — Z 大專學生研究計畫及博士後 — NSC97-2811-B-037-008 — 9 博士後研究員
博士後研究--鄒協成( )
|
2008/11/01 ~ 2009/08/31 |
| 115 |
096 — I 國衛院 — NHRI-EX97-9624SI —
以抗聚乙二醇單鏈Fab膜抗體當報告基因以造影基因於活體內的表現( )
|
2008/01/01 ~ 2008/12/31 |
| 116 |
096 — N 國科會(原科技部) — NSC96-2320-B-037-010-MY3 — 1 個人型
創新疾病易感性基因型分析技術的研發(1/3)( )
|
2007/08/01 ~ 2010/07/31 |
| 117 |
096 — N 國科會(原科技部) — NSC97-3112-B-037-001 — 1 個人型
以人類化抗體當報告基因--非侵犯性造影基因於活體內的表現(3/3)( )
|
2008/05/01 ~ 2009/07/30 |
| 118 |
096 — OX 其他單位(非研究) — — 7 其他(非計畫)
構築哺乳類株化細胞表達豬瘟病毒E0E2及第二型豬環狀病毒ORF2蛋白抗原一件( )
|
2008/05/20 ~ 2008/12/20 |
| 119 |
096 — Z 大專學生研究計畫及博士後 — NSC96-2811-B-037-008 — 9 博士後研究員
博士後研究--鄒協成( )
|
2007/11/01 ~ 2008/10/31 |
| 120 |
096 — Z 大專學生研究計畫及博士後 — 97-2815-C-037-008-B — 8 大專學生研究計畫
97年度大專學生參與專題研究計畫--章雅純( )
|
2008/07/01 ~ 2009/02/28 |
| 121 |
096 — Z 大專學生研究計畫及博士後 — 97-2815-C-037-009-B — 8 大專學生研究計畫
97年度大專學生參與專題研究計畫--陳挺宇( )
|
2008/07/01 ~ 2009/02/28 |
| 122 |
095 — I 國衛院 — NHRI-EX96-9624SI — 1 個人型
以抗聚乙二醇單鏈Fab膜抗體當報告基因以造影基因於活體內的表現( )
|
2007/01/01 ~ 2007/12/31 |
| 123 |
095 — N 國科會(原科技部) — NSC95-2745-B-037-010-URD — 2 整合型
提昇私校研發能量專案計畫-以[創新醫藥科技研發]為目標之整合性研究計畫-子計畫四:以功能性基因體研發乳癌蛋白質藥物(3/3)( )
|
2006/08/01 ~ 2007/07/31 |
| 124 |
095 — N 國科會(原科技部) — NSC96-3112-B-037-001 — 1 個人型
以人類化抗體當報告基因--非侵犯性造影基因於活體內的表現(2/3)( )
|
2007/05/01 ~ 2008/04/30 |
| 125 |
094 — N 國科會(原科技部) — NSC94-2745-B-037-010-URD — 2 整合型
提昇私校研發能量專案計畫-以[創新醫藥科技研發]為目標之整合性研究計畫-子計畫四:以功能性基因體研發乳癌蛋白質藥物(2/3)( )
|
2005/08/01 ~ 2006/07/31 |
| 126 |
094 — N 國科會(原科技部) — NSC 95-3112-B-037-001- — 1 個人型
以人類化抗體當報告基因--非侵犯性造影基因於活體內的表現(1/3)( )
|
2006/05/01 ~ 2007/04/30 |
| 127 |
094 — X 高奇合作計畫 — 95CM-KMU-09 — 1 個人型
大腸直腸癌血液蛋白腫瘤標記之研究( )
|
2006/04/01 ~ 2007/03/31 |
| 128 |
094 — Z 大專學生研究計畫及博士後 — NSC95-2815-C037-012-B — 8 大專學生研究計畫
大專暑期計畫--吳佩玟( )
|
2006/07/01 ~ 2007/02/28 |
| 129 |
094 — Z 大專學生研究計畫及博士後 — NSC95-2815-C037-013-B — 8 大專學生研究計畫
大專暑期計畫--林延灃( )
|
2006/07/01 ~ 2007/02/28 |
| 130 |
094 — Z 大專學生研究計畫及博士後 — NSC95-2815-C037-014-B — 8 大專學生研究計畫
大專暑期計畫--梁雅珍( )
|
2006/07/01 ~ 2007/02/28 |
| 131 |
093 — N 國科會(原科技部) — NSC93-2745-B-037-012-URD — 2 整合型
提昇私校研發能量專案計畫-以[創新醫藥科技研發]為目標之整合性研究計畫-子計畫四:以功能性基因體研發乳癌蛋白質藥物(1/3)( )
|
2004/08/01 ~ 2005/07/31 |
| 132 |
093 — N 國科會(原科技部) — NSC 94-3112-B-037-001- — 1 個人型
建立非侵犯性的造影系統以追蹤基因於活體內的分布與表現（3/3）( )
|
2005/05/01 ~ 2006/04/30 |
| 133 |
093 — Z 大專學生研究計畫及博士後 — NSC94-2815-C-037-007-B — 8 大專學生研究計畫
( )
|
2005/07/01 ~ 2006/02/28 |
| 134 |
092 — N 國科會(原科技部) — NSC92-2751-B-037-006-Y — 1 個人型
SARS專案研究計劃-以結合棘蛋白之PEPTIDES治療或預防病毒之感染( )
|
2003/11/01 ~ 2004/10/31 |
| 135 |
092 — N 國科會(原科技部) — NSC 93-3112-B-037-002- — 1 個人型
建立非侵犯性的造影系統以追縱基因於活體內的分布與表現(2/3)( )
|
2004/05/01 ~ 2005/04/30 |
| 136 |
091 — N 國科會(原科技部) — NSC91-2320-B-037-046 — 1 個人型
開發新奇的基因療法:以半抗原標定治療分子以治療腫瘤( )
|
2002/08/01 ~ 2003/07/31 |
| 137 |
091 — N 國科會(原科技部) — NSC 92-3112-B-037-001- — 1 個人型
建立非侵犯性的造影系統之追蹤基因於活體內的分佈與表現( )
|
2003/05/01 ~ 2004/04/30 |
| 138 |
090 — N 國科會(原科技部) — NSC90-2320B-037-055 — 1 個人型
開發無侵犯性的造影係統以追蹤活體內基因之表現與分布(Noninvasive imaging for gene expression in living animals)
|
2001/10/01 ~ 2002/07/31 |
Patent
| NO | Patent Name | Country | Certified Date | Patent No |
|---|---|---|---|---|
| 1 | 微量細胞核酸檢測晶片之方法 | 中華民國 | 2007/10/01 | I287581 |
| 2 | 大環四胺基單醯胺基三羧酸基雙氟甲苯基醣類化合物作為配位子之具生物活性順磁性金屬錯合物 | 中華民國 | 2009/09/11 | I314456 |
| 3 | 複合式多標的癌細胞冷光偵測方法 | 中華民國 | 2013/03/11 | I388832 |
| 4 | 重組的核?酸序列、包含其之細胞或載體、所編碼出之單鏈抗聚乙二醇膜抗體與造影套組 | 中華民國 | 2013/03/21 | I390040 |
| 5 | 重組的核?酸序列、包含其之細胞或載體、所編碼出之單鏈抗聚乙二醇膜抗體與包含其之細胞的使用方法 | 美國 | 2013/08/13 | 8,507,207 |
| 6 | 可定量任何聚乙二醇分子與其修飾物之抗聚乙二醇表現細胞 | 中華民國 | 2013/02/21 | I386645 |
| 7 | 自動呈色且分子量規則之蛋白質分子量標記套組及其製備方法 | 中華民國 | 2015/01/11 | I468517 |
| 8 | 自動呈色且分子量規則之蛋白質分子量標記套組及其製備方法 | 美國 | 2014/07/29 | 8,791,240 |
| 9 | 可定量任何聚乙二醇分子與其修飾物之抗聚乙二醇表現細胞 | 美國 | 2016/05/03 | 9,329,180 |
| 10 | 二級抗體所辨識之抗原決定位及其用途 | 中華民國 | 2017/08/01 | I593967 |
| 11 | 一種可屏蔽抗體活性的閉鎖器 | 中華民國 | 2017/05/11 | I582111 |
| 12 | 二級抗體所辨識之抗原決定位及其用途 | 美國 | 2016/10/04 | 9,458,243 |
| 13 | 雙功能抗體用於治療癌症 | 中華民國 | 2016/12/01 | I560201 |
| 14 | 一種可屏蔽抗體活性的閉鎖器 | 世界專利(澳洲) | 2019/06/13 | 2014274215 |
| 15 | 一種可屏蔽抗體活性的閉鎖器 | 世界專利(加拿大) | 2023/09/05 | 2,913,051 |
| 16 | 一種可屏蔽抗體活性的閉鎖器(俄羅斯) | 世界專利(歐亞專利組織) | 2020/05/28 | 035322 |
| 17 | 一種可屏蔽抗體活性的閉鎖器 | 世界專利(以色列) | 2020/07/31 | 242772 |
| 18 | 一種可屏蔽抗體活性的閉鎖器 | 世界專利(南非) | 2017/05/31 | 2015/08673 |
| 19 | 一種可屏蔽抗體活性的閉鎖器 | 世界專利(日本) | 2019/07/17 | 6545666 |
| 20 | 一種可屏蔽抗體活性的閉鎖器 | 世界專利(墨西哥) | 2020/02/12 | 371757 |
| 21 | 用于蛋白??物失活的抗体?扣 | 世界專利(中國) | 2019/09/17 | 3529002 |
| 22 | 一種可屏蔽抗體活性的閉鎖器(瑞士、德、英、法) | 世界專利(歐盟) | 2020/01/22 | 3003370 |
| 23 | 一種可屏蔽抗體活性的閉鎖器 | 世界專利(印度) | 2022/07/01 | 400696 |
| 24 | 一種可屏蔽抗體活性的閉鎖器 | 世界專利(南韓) | 2020/11/18 | 102182485 |
| 25 | 一種可屏蔽抗體活性的閉鎖器 | 世界專利(美國) | 2020/04/28 | 10,633,453 |
| 26 | 具抑制細菌葡萄醣醛酸?活性之?唑並 [4，3-c] ??衍生物 | 中華民國 | 2018/02/11 | I614251 |
| 27 | 用以滅活蛋白質藥物的鎖定抗體 | 世界專利(香港) | 2020/09/30 | 1221426 |
| 28 | 雙功能抗體及其用途 | 世界專利(日本) | 2018/12/14 | 6447887 |
| 29 | 雙功能抗體及其用途 | 世界專利(新加坡) | 2021/11/18 | 11201606791Y |
| 30 | 二級抗體所辨識之抗原決定位及其用途 | 美國 | 2019/01/15 | 10,180,433 |
| 31 | ?功能抗体及其用途 | 世界專利(中國) | 2020/03/10 | 3713675 |
| 32 | 雙功能抗體及其用途 | 世界專利(南韓) | 2019/04/17 | 10-1971770 |
| 33 | 雙功能抗體及其用途 | 世界專利(美國) | 2019/01/29 | 10,188,742 |
| 34 | 雙功能抗體及其用途(德英法) | 世界專利(歐盟) | 2020/07/15 | 3126398 |
| 35 | 雙功能抗體用於修飾聚乙二醇化物質之用途 | 中華民國 | 2019/03/11 | I653244 |
| 36 | 具抑制細菌葡萄醣醛酸?活性之?唑並 [4，3-c] ??衍生物 | 世界專利(中國) | 2021/08/27 | 4641308 |
| 37 | 具抑制細菌葡萄醣醛酸?活性之?唑並[4，3-c]??衍生物(德、英、法) | 世界專利(歐盟) | 2020/02/12 | 3302060 |
| 38 | 具抑制細菌葡萄醣醛酸?活性之?唑並 [4，3-c] ??衍生物 | 世界專利(美國) | 2021/10/05 | 11,135,206 |
| 39 | 具抑制細菌葡萄醣醛酸?活性之?唑並 [4，3-c] ??衍生物 | 世界專利(日本) | 2019/11/01 | 6607962 |
| 40 | 雙功能抗體及其用途 | 中華民國 | 2019/11/21 | I677506 |
| 41 | 藉由預靶向的雙特異性聚乙二醇結合抗體將聚乙二醇化試劑條 件性內吞進目標細胞用於診斷和治療 | 中華民國 | 2021/10/11 | I742283 |
| 42 | 雙功能抗體及其用途 | 世界專利(美國) | 2021/06/22 | 11,040,111 |
| 43 | 雙功能抗體及其用途 | 世界專利(美國) | 2022/06/28 | 11,369,690 |
| 44 | 控制蚊媒傳染疾病傳播之微生物製劑 | 中華民國 | 2021/05/21 | I728264 |
| 45 | 具抑制細菌葡萄醣醛酸?活性之?唑並[4，3-c]??衍生物 | 世界專利(美國) | 2021/07/06 | 11,052,072 |
| 46 | 具抑制細菌葡萄醣醛酸?活性之?唑並[4，3-c]??衍生物 | 世界專利(歐盟) | 2021/10/13 | 3662751 |
| 47 | ?功能抗体及其用途 | 世界專利(中國) | 2022/10/21 | 5525981 |
| 48 | 雙功能抗體及其用途(英、法、德) | 世界專利(歐盟) | 2023/09/27 | 3725812 |
| 49 | 具抑制細菌葡萄醣醛酸?活性之?唑並 [4，3-c] ??衍生物 | 世界專利(中國) | 2021/10/26 | 4751135 |